Core Insights - On October 16, Laimei Pharmaceutical experienced a stock price increase of 7.14%, with a trading volume of 381 million yuan [1] - The company reported a financing buy-in amount of 35.74 million yuan and a net financing buy-in of 16.47 million yuan on the same day [1] - As of October 16, the total financing and securities lending balance for Laimei Pharmaceutical was 209 million yuan, representing 4.12% of its market capitalization [1] Financing Summary - On October 16, Laimei Pharmaceutical had a financing buy-in of 35.74 million yuan, with a current financing balance of 209 million yuan, which is above the 70th percentile of the past year [1] - The company repaid 1,800 shares of securities lending and sold 4,800 shares, with a selling amount of 23,000 yuan calculated at the closing price [1] - The securities lending balance was 12.34 million yuan, also exceeding the 70th percentile of the past year [1] Business Performance - As of September 30, Laimei Pharmaceutical had 35,200 shareholders, a decrease of 0.95% from the previous period, with an average of 30,004 circulating shares per shareholder, an increase of 0.96% [2] - For the first half of 2025, the company reported operating revenue of 377 million yuan, a year-on-year decrease of 1.19%, and a net profit attributable to shareholders of -31.38 million yuan, a significant decrease of 2462.45% [2] Dividend and Shareholding - Since its A-share listing, Laimei Pharmaceutical has distributed a total of 280 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders of Laimei Pharmaceutical saw the exit of the Huaxia CSI 500 Index Enhanced A fund from the list [3]